RNAi for the Masses

RNA interference (RNAi), discussed previously in The Scientist,1 is a post-transcriptional, targeted gene-silencing technique that uses double-stranded RNA (dsRNA) to degrade messenger RNA (mRNA) containing the same sequence as the dsRNA. The process occurs in at least two steps: an endogenous ribonuclease cleaves the longer dsRNA into shorter, 21- or 22-nucleotide-long RNAs, termed "small interfering RNAs" or siRNAs. The smaller RNA segments then mediate the degradation of the target mRNA.2 Rec

Written byAileen Constans
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Long dsRNAs have been used successfully for RNAi studies in Drosophila and Caenorhabditis elegans, but RNA interference has been difficult to achieve in mammalian cell cultures. "It turns out that there's an antiviral response in mammalian cells where when you introduce long double-stranded RNAs, the cells apoptose and die," explains David Brown, senior R&D scientist at Austin, Texas-based Ambion. "That was a problem." Last May, however, researchers at the Max Planck Institute for Biophysical Chemistry in G¨ottingen, Germany, reported that transfection of mammalian cells with the shorter siRNAs avoided this antiviral response and did in fact lead to a reduction in mRNA levels for the gene targeted by the siRNAs.3

Chemical synthesis of siRNAs, however, can be expensive, especially for labs that do not have access to a core synthesis facility. One chemically synthesized siRNA can cost hundreds of dollars, making the prospect of using this technique for gene knockout ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies